Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE AND ACETIC ACID versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE AND ACETIC ACID versus MAGNACORT.
HYDROCORTISONE AND ACETIC ACID vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category D/X
Category C
Corticosteroid
Corticosteroid